Armata Pharmaceuticals, Inc.
ARMP · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,159 | $2,169 | $491 | $1,235 |
| % Growth | -46.6% | 341.8% | -60.2% | – |
| Cost of Goods Sold | $370 | $366 | $377 | $380 |
| Gross Profit | $789 | $1,803 | $114 | $855 |
| % Margin | 68.1% | 83.1% | 23.2% | 69.2% |
| R&D Expenses | $5,824 | $6,394 | $5,429 | $8,450 |
| G&A Expenses | $0 | $2,619 | $3,253 | $3,323 |
| SG&A Expenses | $2,741 | $2,619 | $3,253 | $3,323 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$366 | -$377 | -$379 |
| Operating Expenses | $8,565 | $8,647 | $8,305 | $11,394 |
| Operating Income | -$7,776 | -$6,844 | -$8,191 | -$10,539 |
| % Margin | -670.9% | -315.5% | -1,668.2% | -853.4% |
| Other Income/Exp. Net | -$18,899 | -$9,451 | $1,660 | $13,139 |
| Pre-Tax Income | -$26,675 | -$16,295 | -$6,531 | $2,600 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26,675 | -$16,295 | -$6,531 | $2,600 |
| % Margin | -2,301.6% | -751.3% | -1,330.1% | 210.5% |
| EPS | -0.74 | -0.45 | -0.18 | 0.072 |
| % Growth | -64.4% | -150% | -350.3% | – |
| EPS Diluted | -0.74 | -0.45 | -0.18 | 0.044 |
| Weighted Avg Shares Out | 36,226 | 36,193 | 36,185 | 36,183 |
| Weighted Avg Shares Out Dil | 36,226 | 36,193 | 36,185 | 59,082 |
| Supplemental Information | – | – | – | – |
| Interest Income | $90 | $108 | $59 | $130 |
| Interest Expense | $4,346 | $3,808 | $3,602 | $3,280 |
| Depreciation & Amortization | $370 | $366 | $377 | $380 |
| EBITDA | -$21,959 | -$12,121 | -$2,552 | $6,260 |
| % Margin | -1,894.7% | -558.8% | -519.8% | 506.9% |